252 related articles for article (PubMed ID: 22464177)
21. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
22. p63 is useful in the diagnosis of mammary metaplastic carcinomas.
Tse GM; Tan PH; Chaiwun B; Putti TC; Lui PC; Tsang AK; Wong FC; Lo AW
Pathology; 2006 Feb; 38(1):16-20. PubMed ID: 16484002
[TBL] [Abstract][Full Text] [Related]
23. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
[TBL] [Abstract][Full Text] [Related]
24. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas.
Popnikolov NK; Ayala AG; Graves K; Gatalica Z
Am J Clin Pathol; 2003 Aug; 120(2):161-7. PubMed ID: 12931544
[TBL] [Abstract][Full Text] [Related]
25. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
26. Increased alpha-B-crystallin expression in mammary metaplastic carcinomas.
Chan SK; Lui PC; Tan PH; Yamaguchi R; Moriya T; Yu AM; Shao MM; Hliang T; Wong SI; Tse GM
Histopathology; 2011 Aug; 59(2):247-55. PubMed ID: 21884203
[TBL] [Abstract][Full Text] [Related]
27. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
28. Claudin expression in breast cancer: high or low, what to expect?
Ricardo S; Gerhard R; Cameselle-Teijeiro JF; Schmitt F; Paredes J
Histol Histopathol; 2012 Oct; 27(10):1283-95. PubMed ID: 22936447
[TBL] [Abstract][Full Text] [Related]
29. Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation.
Soini Y; Takasawa A; Eskelinen M; Juvonen P; Kärjä V; Hasegawa T; Murata M; Tanaka S; Kojima T; Sawada N
J Clin Pathol; 2012 May; 65(5):431-6. PubMed ID: 22396552
[TBL] [Abstract][Full Text] [Related]
30. Claudin expression in rectal well-differentiated endocrine neoplasms (carcinoid tumors).
Ishida M; Kushima R; Okabe H
Oncol Rep; 2009 Jan; 21(1):113-7. PubMed ID: 19082451
[TBL] [Abstract][Full Text] [Related]
31. Metaplastic and medullary mammary carcinomas do not express mammaglobin.
Reyes C; Gomez-Fernández C; Nadji M
Am J Clin Pathol; 2012 May; 137(5):747-52. PubMed ID: 22523213
[TBL] [Abstract][Full Text] [Related]
32. Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].
Weigelt B; Ng CK; Shen R; Popova T; Schizas M; Natrajan R; Mariani O; Stern MH; Norton L; Vincent-Salomon A; Reis-Filho JS
Mod Pathol; 2015 Mar; 28(3):340-51. PubMed ID: 25412848
[TBL] [Abstract][Full Text] [Related]
33. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
34. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
35. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
36. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathologic and prognosis features of Claudin-low breast cancers].
Xu J; Lan KT; Su TH; Li ZF; Wan Y; Gu QQ; Zou PC; Zou X
Zhonghua Bing Li Xue Za Zhi; 2017 Sep; 46(9):634-639. PubMed ID: 28910875
[No Abstract] [Full Text] [Related]
38. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
39. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition.
Zhang Y; Toy KA; Kleer CG
Mod Pathol; 2012 Feb; 25(2):178-84. PubMed ID: 22080057
[TBL] [Abstract][Full Text] [Related]
40. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A
Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
